The arterial blood gas machine market was estimated at USD 584.5 million in 2019 and is projected to grow with a CAGR of 5.0%.
Blood gas analyzers are used in the diagnosis of several physiological parameters, such as blood vessel hemorrhage, diabetes, drug overdose, and shock testing, including hydrogen ion concentration, electrolytes, and oxygen concentration. Blood gas levels provide accurate results for acid-base balance, blood gases, and other electrolyte balance. ABG is helpful in the diagnosis of a variety of metabolic acid/base disorders, ventilation complications, and hypoxemia in the intensive care unit. Following the onset of therapy, repeat ABG may assess the efficacy of the intervention (e.g., when mechanical ventilation is performed for respiratory failure) and also indicate the degree of respiratory and renal compensation for a given acid/base condition.
ABGs are particularly helpful in operating theatre where acid/base status can dynamically change during cardiopulmonary bypass, one-lung ventilation, transplant surgery, and urological procedures. Its analysis is also helpful where tight control of partial CO2 pressure is necessary for better patient outcomes; for example, in neurosurgical cases where the impact of carbon dioxide on intracranial pressure (ICP) may be crucial. Additionally, blood gas testing is often recommended for patients assisted by the ventilator, undergoing respiratory distress evaluation to offer insights on the patient's oxygen level.
An increasing number of patients admitted in intensive care units, emergency care centers, and operation theaters, growing demand for high performance and integrated systems, and increasing affordability of patients drive the market growth. The global geriatric population is growing at a significant rate, further rising the number of patients seeking medical care in emergency departments, critical care units, and operating rooms as they are highly susceptible to a myriad of diseases. The global geriatric population aged 65 and above is expected to grow from 7% in 2000 to 16% by 2050, as per the World Health Organization (WHO).
The arterial blood gas machine market’s most prominent driver is the rapid innovations and advancements in technology. The development of innovative devices from the bench-top to portable, mobile, and elegant point-of-care devices provides an impetus to the market growth. In addition, the expanded test kit market integrates blood gas and electrolyte analysis features to include multiple electrolytes, bilirubin, creatinine, and single-sample blood urea nitrogen testing. For instance, Sphere Medical Ltd, a U.K. based company, developed a blood gas analyzer that includes an application-specific integrated circuit (ASIC) and a disposable sensor.
Increasing demand for high efficiency and integrated systems, suitable treatment in trauma centers and ICU, delivery of fast and credible results, and high turnaround time of blood gas analyzers drives the market growth. The ability of blood gas analyzers to integrate with electronic health/medical records (EHRs/EMRs) has improved the workflow and limited manual errors. Increasing application of ABG machines in surgical procedures, such as hypoventilation, endotracheal tube placement, and esophageal intubation, due to higher sensitivity, improved patient safety profile, and faster detection of respiratory insufficiency provides an impetus to the market growth.
Globally, the healthcare expenditure for the treatment of chronic diseases, such as cancer and chronic respiratory diseases, has been witnessing a significant surge. Private organizations and governments are channelizing efforts to formulate favorable initiatives to reduce healthcare expenditure, which includes encouraging patients to undergo regular diagnostic examinations. As per the WHO, the global incidence of cancer was 14.1 million in 2012 and is projected to reach 23.6 million by 2030, further prompting the need for efficient blood gas machines.
The portable blood gas machines segment held the largest market share in 2018 and is projected to dominate the market during the forecast period on account of its ability to render instantaneous test results and faster turnaround time. The segment’s primary driver is the increasing demand for point-of-care blood gas machines.
The benchtop ABG segment leads the market on account of its increasing applications in umpteen hospital settings. Benchtop analyzers offer a range of benefits such as individual biosensor technology, broad test menu, and low cost of operation, further driving the segment growth.
The ICU segment holds the highest market share during the forecast period owing to the increasing number of patients admitted in intensive care units and emergency wards. Increasing demand of ABG machine to track the pH levels, carbon dioxide, and oxygen in the blood and determine the occurrence of medical conditions such as heart failure, kidney failure, chemical poisoning, drug overdose, and hemorrhage drives the segment growth.
ABG machines are the leading diagnostic intervention for patients suffering from COVID-19. All the leading markets are working on optimizing the availability of blood gas and other blood electrolyte estimation machines. Several market players in ABG machine market are actively working to respond to the coronavirus outbreak, further driving the adoption of ABG machines. For instance, Siemens Healthineers introduced the blood gas analyzer's portfolio as blood gas screening plays a vital role in managing coronavirus infected patients.
North America dominates the arterial blood gas machines market as the region is backed by the presence of umpteen healthcare practitioners. Increasing patient awareness, availability of well-established healthcare infrastructure, and government support drive the regional market growth. As per the Centers for Disease Control and Prevention (CDC) report, in the U.S., around 1.7 million emergency department visits were recorded in 2017. The strong presence of domestic and international medical device manufacturers supplying ABG machines to both the developed and emerging markets provides an impetus to the regional market growth.
Europe’s arterial blood gas machines market is backed by the presence of prominent medical device companies and the growing geriatric population. Apart from this, increasing prevalence of cancer and other chronic disorders, rising public funding in healthcare, and favorable government initiatives provide an impetus to the market growth. Recently, Siemens Healthineers, a German-based medical device company, launched RAPID Point 500e Blood Gas Analyzer, a trusted instrument in Europe's endeavor, to combat COVID-19 and help address unprecedented demand for blood gas testing.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
In July 2017, Siemens Healthineers acquired of Epocal Inc. to expand its blood gas portfolio in the point-of-care segment
In April 2017, Radiometer, aS. based diagnostic devices company launched the advanced ABL90 FLEX PLUS blood gas analyzer in Canada. The ABL90 FLEX PLUS can measure 17 different parameters in 35 seconds using only 65 µL of the blood sample and is in compliance with Clinical Laboratory Improvement Amendments (CLIA) guidelines